R247
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 105
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.020
- PEROXISOME+0.010
- BILE_ACID_METABOLISM+0.000
- HEME_METABOLISM+0.000
- FATTY_ACID_METABOLISM-0.040
- UV_RESPONSE_DN-0.050
- DNA_REPAIR-0.080
- INTERFERON_ALPHA_RESPONSE-0.080
- KRAS_SIGNALING_DN-0.100
- SPERMATOGENESIS-0.100
Top 10 suppressed
- E2F_TARGETS-0.580
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.540
- G2M_CHECKPOINT-0.500
- CHOLESTEROL_HOMEOSTASIS-0.490
- TNFA_SIGNALING_VIA_NFKB-0.490
- ANGIOGENESIS-0.450
- IL6_JAK_STAT3_SIGNALING-0.420
- INFLAMMATORY_RESPONSE-0.420
- HYPOXIA-0.410
- MTORC1_SIGNALING-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR11296802 | — | — | 0.930 |
| 2 | SRR8943008 | — | — | 0.925 |
| 3 | EPT0291 | EPN | EPN Tumor | 0.923 |
| 4 | TCGA-CF-A27C-01A-11R-A16R-07 | — | — | 0.920 |
| 5 | C3N-03420 | — | cohortA1 | 0.916 |
| 6 | SRR8613727 | — | D | 0.914 |
| 7 | SRR8943010 | — | — | 0.912 |
| 8 | SRR23303775 | — | — | 0.907 |
| 9 | TCGA-CF-A5U8-01A-11R-A28M-07 | — | — | 0.902 |
| 10 | TCGA-ZF-A9R5-01A-12R-A42T-07 | — | — | 0.896 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 2 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.020 | Remibrutinib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |